Male InfertilityAndrofertiNCT03466229
Impact of Antioxidant Treatment on DNA Fragmentation Index
A study testing Androferti in people with Male Infertility, run by Region Skane.
Trial summary
Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Male Infertility
- What is being tested?
- Androferti
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 79 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2015to 31 Dec 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Referred due to infertility
- Age: 18-50 years,
- Non-smoking,
- Sperm DNA Fragmentation Index >25%
Who cannot join
- Body mass index (BMI) ≥30,
- FSH outside the normal range of 2-8 IU/L,g)
- LH outside the normal range of 2-10 IU/L,
- T < 10nmol/L
- Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
- History of anabolic steroids use,
- Taking antioxidant supplementation the last six months.
About this study
Official title: Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity
Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.
Read the detailed description
In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.
Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.
Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient ~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.
The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.
Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.
The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .
The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.
- Conditions
- Male Infertility
- Being tested
- Androferti, Placebo
- Keywords
- sperm DNA strand breaks, antioxidants
- Medical subject headings
- Infertility, Male
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AndrofertiDietary supplement
PlaceboDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Antioxidant | Active comparator | Androferti - 1 twice per day Receives: Dietary Supplement: Androferti |
| Placebo | Placebo comparator | Placebo - 1 twice per day Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
DFI_3
3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin
Measured: Change in DNA Fragmentation Index from Baseline to 3 months
DFI_6
6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay
Measured: Change in DNA Fragmentation Index from Baseline to 6 months
Secondary outcomes (6)
Concentration_3
Change sperm concentration 3 months
Measured: Change in sperm concentration from baseline to 3 months in millions/mL
Concentration_6
Change sperm concentration 6 months
Measured: Change in sperm concentration from baseline to 6 months in millions/mL
Motility_3
Change sperm motility 3 months
Measured: Change in sperm motility from baseline to 3 months in %
Motility_6
Change sperm motility 6 months
Measured: Change in sperm motility from baseline to 6 months in %
Morphology_3
Change sperm morphology 3 months
Measured: Change in sperm morphology from baseline to 3 months in %
Morphology_6
Change sperm morphology 6 months
Measured: Change in sperm morphology from baseline to 6 months in %
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2018
- Study start1 Jul 2015
- Primary completion31 Dec 2016
- Study completion31 Dec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Male InfertilityStudies of the same condition, open and under way.
- More trials run by Region SkaneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double blind randomised placebo controlled study
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 79 participants (actual)
Sponsor and investigators
- Lead sponsor
- Region Skane
- Sponsor type
- University, hospital or other
- Collaborators
- Q-Pharma, Octean
- Responsible party
- Principal investigator, Aleksander Giwercman, Region Skane
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03466229
- Sponsor's protocol ID
- Androferti
- Acronym
- Androferti
- Status last verified
- Mar 2018
- First submitted
- 4 Mar 2018
- Last updated
- 16 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Plan to share IPD has not yet been discussed
Publications
Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology. 2018 Nov;6(6):811-816. doi: 10.1111/andr.12547. Epub 2018 Oct 8.
PubMed 30298673
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity
- ClinicalTrials.gov ID
- NCT03466229
- Acronym / sponsor ID
- Androferti / Androferti
- Conditions
- Male Infertility
- Keywords
- sperm DNA strand breaks, antioxidants
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 79 participants (actual)
- Lead sponsor
- Region SkaneUniversity, hospital or other
- Collaborators
- Q-Pharma, Octean
- Study start
- 1 Jul 2015 (actual)
- Primary completion
- 31 Dec 2016 (actual)
- Study completion
- 31 Dec 2016 (actual)
- First posted
- 15 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.
Detailed description
In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.
Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.
Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient ~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.
The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.
Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.
The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .
The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- Double blind randomised placebo controlled study
| Arm | Type | Receives |
|---|---|---|
| Antioxidant | Active comparator | Dietary Supplement: AndrofertiAndroferti - 1 twice per day |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo - 1 twice per day |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Referred due to infertility
- Age: 18-50 years,
- Non-smoking,
- Sperm DNA Fragmentation Index >25%
Key exclusion criteria (7 listed)
- Body mass index (BMI) ≥30,
- FSH outside the normal range of 2-8 IU/L,g)
- LH outside the normal range of 2-10 IU/L,
- T < 10nmol/L
- Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Androferti | Dietary supplement | Antioxidant |
| Placebo | Dietary supplement | Placebo |
Primary outcome
DFI_3
Time frame: Change in DNA Fragmentation Index from Baseline to 3 months
3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin
DFI_6
Time frame: Change in DNA Fragmentation Index from Baseline to 6 months
6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay
6 secondary outcomes
Concentration_3
Time frame: Change in sperm concentration from baseline to 3 months in millions/mL
Concentration_6
Time frame: Change in sperm concentration from baseline to 6 months in millions/mL
Motility_3
Time frame: Change in sperm motility from baseline to 3 months in %
Motility_6
Time frame: Change in sperm motility from baseline to 6 months in %
Morphology_3
Time frame: Change in sperm morphology from baseline to 3 months in %
Morphology_6
Time frame: Change in sperm morphology from baseline to 6 months in %
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2018.
- Derived from this study: PubMed 30298673Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology. 2018 Nov;6(6):811-816. doi: 10.1111/andr.12547. Epub 2018 Oct 8.
- Individual participant dataSharing planned: Undecided. Plan to share IPD has not yet been discussed
Related trials for Male Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruitingPhase 3
Comparative Study of Post-Varicocelectomy Myo-inositol vs. Antioxidants vs. Surgery Alone in Infertile Men
Myo-inositol, Post Varicocelectomy
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Not yet recruiting
Sperm, Exposure and Endocrine Disruptors
Fertility, Male Fertility
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Androferti in people with Male Infertility, run by Region Skane.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DFI_3 (time frame: Change in DNA Fragmentation Index from Baseline to 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03466229, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2018.